EUCTR2016-000569-21-FR进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 449
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •For a complete list of study inclusion criteria, please refer to study protocol (Sections 4.2):
- •1) Male or female subjects who are =18 years of age, on the day of signing informed consent.
- •2) Have a diagnosis of RA (2010 ACR/EULAR criteria for RA), and are ACR functional class I-III.
- •3) Have =6 swollen joints (from a SJC66) and =6 tender joints (from a TJC68) at both screening and Day 1 (need not be the same joints)
- •4) Have serum CRP = 4 mg/L.
- •5) Ongoing treatment with a stable prescription of 1 or 2 permitted csDMARD(s) as described in the study protocol (section 4.2)
- •6) Have received at least one bDMARD for the treatment of RA to which they have had an inadequate response or intolerance. An inadequate response is defined as documented continued or recurrent disease activity after at least 12 weeks of treatment with any investigational or licensed bDMARD, including biosimilars, for the treatment of RA. Intolerance is defined as any documented adverse effect associated with a bDMARD used
- •according to its respective label. There is no limit to the prior number of bDMARDs that may have been used by the subject, however, the subject must not be on a bDMARD at Day 1 (appropriate wash out needs to be satisfied according to the protocol) or during the study.
- •7) Females of childbearing potential (defined in protocol Appendix 5) must have a negative pregnancy test at screening and Day 1
- •8) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
- •9) Lactating female subjects must agree to discontinue nursing from Screening through the end of their study participation
- •10) Meet one of the tuberculosis (TB) Screening criteria described in the protocol (section 4.2)
- •11) Able and willing to sign the informed consent as approved by the IRB/IEC. Written consent must be provided before initiating any screening evaluations. Subjects must have read and understood the ICF, must fully understand the requirements of the study, and must be willing to comply with all study visits and assessments subjects who cannot read or understand the ICF may not be enrolled by a guardian or any other individual.
- •12) Subjects receiving non-prohibited medication for any reason should be on a stable dose (defined as no change in prescription) within 7 days or 5 half-lives (whichever is longer) prior to the first administration of study drug on Day 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 211
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 211
排除标准
- •For a complete list of study exclusion criteria, please refer to study protocol (Sections 4.3):
- •1) Prior treatments for RA as defined in Section 4.3 of the protocol
- •2) Known hypersensitivity or allergy to the study drug(s), its metabolites, or formulation excipients.
- •3) Oral steroids at a dose >10 mg/day of prednisone equivalent or a prescription for oral steroids which has changed within 4 weeks of Day 1.
- •4) Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to Day 1.
- •5) Use of nonsteroidal anti-inflammatory drugs (NSAID(s) which have not been at a stable dose (defined as no change in prescription) for at least 2 weeks prior to Day 1.
- •6) Administration of a live/ attenuated vaccine within 30 days prior to Day 1, or planned during the study.
- •7) Participation in any clinical study of an investigational drug/device within 4 weeks or 5 half-lives prior to Screening, whichever is longer. Exposure to investigational biologics should be discussed with the sponsor.
- •8) Have undergone surgical treatments for RA including synovectomy or arthroplasty in >4 joints and/or within the last 12 weeks prior to Screening
- •9) Have any chronic, uncontrolled medical condition, which would put the subject at increased risk during study participation, such as uncontrolled: diabetes, hypertension, morbid obesity, thyroid, adrenal, pulmonary, hepatic, renal, neurologic or psychiatric disease, or other disease of concern, as per judgment of investigator
- •10) Have a history of major surgery (requiring regional block or general anaesthesia) within the last 12 weeks prior to Screening or planned major surgery during the study.
- •11) Have a moderately to severely active, generalized musculoskeletal disorder that would interfere with assessment of study parameters or increase risk to the subject by participating in the study
- •12) Active autoimmune disease other than those listed above, that would interfere with assessment of study parameters or increase risk to the subject by participating in the study, eg, inflammatory bowel disease, uncontrolled thyroiditis, systemic vasculitis, transverse myelitis or uveitis.
- •13) History of or current moderate to severe congestive heart failure (New York Heart Association [NYHA] class III or IV), or within the last 6 months, a cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or new or significant ECG finding at Screening, or any other cardiovascular condition which, in the opinion of the investigator, would put the subject at risk by participation in the study.
- •14) History of malignancy within the past 5 years prior to Screening (except for adequately treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ with no evidence of recurrence).
- •15) History of lymphoproliferative disease or current lymphoproliferative disease.
- •16) History of gastrointestinal perforation.
- •17) History of organ or bone marrow transplant.
- •18) Positive serology for human immunodeficiency virus (HIV) 1 or 2
- •19) Evidence of active Hepatitis C Virus (HCV) infection
- •20) Evidence of ac
研究者
相似试验
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive CrisesPatients with a diagnosis of sickle cell disease who have experienced between 2 and 10 vaso-occlusive crises in the 12 months preceding enrollment in this study.SCD, vaso-occlusive crisis, blood disorders, hemoglobin, red blood cells, sickle-like shape, mutation in hemoglobin gene, sickle-cell trait, sickle-cell crisis, Sickle Cell Disease SCD, Hydroxyurea/ Hydroxycarbamide Therapy, SCALBCTR2021064791Global Blood Therapeutics, Inc.240
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with PsoriasisModerate to severe plaque psoriasisMedDRA version: 12.0Level: LLTClassification code 10037153Term: PsoriasisEUCTR2009-013539-39-FRAmgen Inc175
未知
1 期
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese SubjectsHealthy Japanese SubjectJPRN-jRCT2080223449Eisai Co., Ltd.16
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Multi-centre Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Metastatic Renal Cell CarcinomaEUCTR2005-004078-25-CZGlaxoSmithKline Research & Development Limited400
进行中（未招募）
1 期
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasismoderate to severe palmoplantar psoriasisMedDRA version: 15.1Level: LLTClassification code 10037158Term: Psoriasis palm & solesSystem Organ Class: 100000004858EUCTR2012-005412-25-ESovartis Farmacéutica, S.A.201